Exelixis Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Exelixis Inc 公司

Exelixis, Inc. 是一家腫瘤學公司。該公司已生產了四種上市藥品，其中兩種是其旗艦分子卡博替尼的配方。該公司還在推進和發展其產品線組合，包括其主要研究資產 zanzalintinib。卡博替尼是多種酪氨酸激酶的抑制劑，包括 MET、AXL、VEGF 受體和 RET，還被批准作爲 CABOMETYX 片劑用於晚期腎細胞癌、先前治療過的肝細胞癌和先前治療過的放射性碘難治性分化性甲狀腺癌，以及作爲 COMETRIQ 膠囊用於進行性轉移性髓樣甲狀腺癌。該公司的另外兩種產品是 COTELLIC，一種 MEK 抑制劑，被批准作爲多種聯合方案的一部分用於治療特定形式的晚期黑色素瘤，以及 MINNEBRO，一種口服、非甾體、選擇性鹽皮質激素受體阻滯劑，在日本被批准用於治療高血壓。

Exelixis Inc簡介



公司代碼EXEL

公司名稱Exelixis Inc

上市日期Apr 11, 2000

CEODr. Michael M. Morrissey, Ph.D.

員工數量1147

證券類型Ordinary Share

年結日Apr 11

公司地址1851 Harbor Bay Parkway

城市ALAMEDA

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編94502

電話16508377000

網址https://www.exelixis.com/

公司代碼EXEL

上市日期Apr 11, 2000

CEODr. Michael M. Morrissey, Ph.D.

Exelixis Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Michael M. Morrissey, Ph.D.

President, Chief Executive Officer, Director

2.27M

-4.42%

Dr. Stelios B. Papadopoulos, Ph.D.

Independent Chairman of the Board, Co-Founder

1.27M

+0.78%

Mr. Jeffrey J. Hessekiel, J.D.

Executive Vice President, General Counsel

410.70K

-12.57%

Dr. Dana T. Aftab, Ph.D.

Executive Vice President - Research and Development

359.32K

-8.22%

Mr. Jack L. Wyszomierski

Independent Director

340.04K

-2.17%

Mr. Patrick Joseph Haley

Executive Vice President - Commercial

258.52K

-25.63%

Dr. George H. Poste, Ph.D.

Independent Director

159.99K

+6.53%

Dr. Maria C. Freire, Ph.D.

Independent Director

81.98K

+13.60%

Ms. Julie Anne Smith

Independent Director

10.57K

+1285.98%

Mr. Robert Lee (Bob) Oliver, Jr.

Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Dr. Michael M. Morrissey, Ph.D.

President, Chief Executive Officer, Director

2.27M

-4.42%

Dr. Stelios B. Papadopoulos, Ph.D.

Independent Chairman of the Board, Co-Founder

1.27M

+0.78%

Mr. Jeffrey J. Hessekiel, J.D.

Executive Vice President, General Counsel

410.70K

-12.57%

Dr. Dana T. Aftab, Ph.D.

Executive Vice President - Research and Development

359.32K

-8.22%

Mr. Jack L. Wyszomierski

Independent Director

340.04K

-2.17%

Mr. Patrick Joseph Haley

Executive Vice President - Commercial

258.52K

-25.63%

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

業務USD

名稱

營收

佔比

CABOMETYX

517.89M

91.14%

License revenues

49.30M

8.68%

COMETRIQ

2.12M

0.37%

Collaboration services revenues

-1.05M

-0.19%

地區USD

名稱

營收

佔比

U.S

524.77M

92.35%

Europe

37.03M

6.52%

Japan

6.46M

1.14%

業務

地區

業務USD

名稱

營收

佔比

CABOMETYX

517.89M

91.14%

License revenues

49.30M

8.68%

COMETRIQ

2.12M

0.37%

Collaboration services revenues

-1.05M

-0.19%

股東統計

更新時間: 8月16日週六

持股股東

股東類型

持股股東

佔比

The Vanguard Group, Inc.

10.18%

BlackRock Institutional Trust Company, N.A.

9.45%

Farallon Capital Management, L.L.C.

5.96%

Renaissance Technologies LLC

5.88%

State Street Investment Management (US)

4.23%

其他

64.31%

持股股東

佔比

The Vanguard Group, Inc.

10.18%

BlackRock Institutional Trust Company, N.A.

9.45%

Farallon Capital Management, L.L.C.

5.96%

Renaissance Technologies LLC

5.88%

State Street Investment Management (US)

4.23%

其他

64.31%

股東類型

持股股東

佔比

Investment Advisor

44.82%

Investment Advisor/Hedge Fund

28.58%

Hedge Fund

15.52%

Research Firm

2.90%

Pension Fund

2.72%

Individual Investor

2.25%

Sovereign Wealth Fund

1.25%

Bank and Trust

0.58%

Family Office

0.19%

其他

1.20%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

1092

260.88M

96.91%

-7.90M

2025Q2

1066

261.07M

96.97%

-18.39M

2025Q1

1059

268.29M

98.20%

-10.58M

2024Q4

992

262.76M

93.66%

-11.36M

2024Q3

924

259.58M

90.96%

-10.18M

2024Q2

908

255.61M

87.75%

-22.29M

2024Q1

905

264.69M

87.26%

-20.82M

2023Q4

882

270.85M

87.07%

-16.64M

2023Q3

847

278.02M

87.32%

-18.15M

2023Q2

833

285.95M

87.85%

-21.34M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

27.41M

10.18%

-1.20M

-4.20%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

25.44M

9.45%

-1.05M

-3.97%

Jun 30, 2025

Farallon Capital Management, L.L.C.

16.04M

5.96%

-2.60M

-13.95%

Jun 30, 2025

Renaissance Technologies LLC

15.82M

5.88%

+995.50K

+6.72%

Jun 30, 2025

State Street Investment Management (US)

11.38M

4.23%

-404.95K

-3.43%

Jun 30, 2025

Fuller & Thaler Asset Management Inc.

8.78M

3.26%

+980.50K

+12.58%

Jun 30, 2025

LSV Asset Management

7.82M

2.9%

-340.89K

-4.18%

Jun 30, 2025

AQR Capital Management, LLC

7.61M

2.83%

+712.19K

+10.33%

Jun 30, 2025

Geode Capital Management, L.L.C.

7.45M

2.77%

+28.29K

+0.38%

Jun 30, 2025

Arrowstreet Capital, Limited Partnership

5.26M

1.95%

+1.58M

+42.93%

Jun 30, 2025

持股ETF



更新時間: 10月6日週一

機構名稱

佔比

iShares Genomics Immunology and Healthcare ETF

3.48%

Invesco Dorsey Wright Healthcare Momentum ETF

3.09%

Tema Oncology ETF

2.99%

First Trust NYSE Arca Biotechnology Index Fund

2.7%

Invesco Biotechnology & Genome ETF

2.24%

SPDR S&P Biotech ETF

2.1%

First Trust NASDAQ Pharmaceuticals ETF

1.92%

Inspire Faithward Mid Cap Momentum ETF

1.84%

AAM Sawgrass US Large Cap Quality Growth ETF

1.83%

First Trust Health Care Alphadex Fund

1.82%

iShares Genomics Immunology and Healthcare ETF

佔比3.48%

Invesco Dorsey Wright Healthcare Momentum ETF

佔比3.09%

Tema Oncology ETF

佔比2.99%

First Trust NYSE Arca Biotechnology Index Fund

佔比2.7%

Invesco Biotechnology & Genome ETF

佔比2.24%

SPDR S&P Biotech ETF

佔比2.1%

First Trust NASDAQ Pharmaceuticals ETF

佔比1.92%

Inspire Faithward Mid Cap Momentum ETF

佔比1.84%

AAM Sawgrass US Large Cap Quality Growth ETF

佔比1.83%

First Trust Health Care Alphadex Fund

佔比1.82%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據